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Sir,  
Apremilast, which is currently licensed for the treatment of psoriasis and 
psoriatic arthritis is a small-molecule inhibitor of phosphodiesterase-4 (PDE-
4), an enzyme responsible for the breakdown of cyclic adenosine 
monophosphate (cAMP) (Torres, 2018).  
An 83-year-old male with psoriasis and psoriatic arthritis was referred to our 
Department of Dermatology with severe plaques and dactylitis of the second 
finger of his right hand. He was overweight (body mass index 29.4 kg/m2), 
had a Psoriasis Area Severity Index (PASI) of 11, and complained of a drastic 
reduction in his quality of life (Dermatology Life Quality Index [DLQI] 23).  
As his medical history included a myocardial infarction and bladder cancer 
respectively two and three years earlier, biological treatment was absolutely 
contraindicated, and he failed to respond to narrow-band ultraviolet B (NB-
UVB) plus methotrexate, the only remaining on-label systemic treatment was 
with apremilast, a PDE-4 inhibitor. After precisely following the induction 
(10mg/day at day 1, 10+10mg/day at day 2, 10+20mg/day at day 3, 20+20mg 
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at day 4, 20+30 mg at day 5, after 30+30mg/daily) and maintenance (30+30 
mg/daily, after day 5) treatment protocol, optimal psoriasis was achieved in 
four weeks, supported by a PASI of 1 and a DLQI of 3.  
However, after eight weeks of follow-up, he complained of relapse marked by 
a PASI of 6 and the sudden onset of a severe bitter taste in his mouth, which 
occurred at the same time as a loss of appetite and a 2 kg weight loss. He 
had no previous history of taste dysfunction, occupational exposure to 
substances causing taste dysfunction, or any drugs traditionally associated 
with dysgeusia, and so an extensive oral and dental evaluation was made in 
order to rule out local causes. The main structures of the oral cavity (soft 
tissues, periodontal bone and teeth) were clinically assessed, and magnetic 
resonance imaging was used to exclude any cranial nerve or structural brain 
disease.  
As the bitter taste appeared acutely and persisted in the absence of any food 
or drink, a diagnosis of phantogeusia was made, apremilast was stopped, and 
topical therapy with calcipotriol monohydrate/betamethasone dipropionate 
was added for three weeks. As the bitter taste resolved after the 
discontinuation of apremilast and re-appeared when the drug was re-
administered, the Naranjo algorithm was used to assess whether it was an 
adverse drug reaction.  
Although apremilast has never been associated with taste dysfunction, drug- 
related changes in taste are frequent and often underestimated in clinical 
trials (Garcia-Doval, 2012). Many drugs can affect a patient’s taste, especially 
those that modify ion channels or cyclic nucleosides such as cGMP, cAMP 
and inositol phosphate (Naik, 2010). As an inhibitor of PDE-4, apremilast 
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increases cAMP levels, and high intracellular levels of cAMP in type II taste 
cells of the tongue, prevents depolarisation and, consequently, message 
delivery (see Figure 1). A bitter taste may be a result of the hyperactivation of 
bitter taste receptors such as T2R or the decreased activation of sweet taste 
receptors such as T1R2/T1R3, and analysis of the regulatory dynamics of 
cAMP-related signalling suggests that apremilast acted on our patient’s 
T1R2/T1R3 receptors. The medical implications of this may be detrimental in 
the case of a diabetic patient ingesting excess sugar in order to suppress the 
bitter taste caused by medication, but taste perception is also involved in the 
neuronal pathways modulating the digestion, absorption, and storage of 
nutrients (Naik, 2010), and a dysfunction in taste perception can decrease a 
patient’s quality of life by altering appetite, body weight, and psychological 
health (DuBois, 2016) or also be an accompanying symptom of burning mouth 
syndrome (Kolkka-Palomaa, 2015).  
In conclusion, it would be worth investigating this side effect further as it may 
greatly affect the compliance of patients being treated for chronic diseases 
such as psoriasis. 
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Figure legend : 
Physiologically, a sweet taste ligand stimulates the G protein-coupled receptor 
(GPCR) which, via trimeric G proteins, activates phospholipase C isoform b2 
(PLCb2) and phosphodiesterase (PDE)-4. In particular, G activates PDE-4, 
which opens cyclic-AMP (cAMP) and, by decreasing cAMP levels, inhibits 
protein kinase A (PKA). PLCb2, which is activated by G, catalyses the 
hydrolysis of phosphatidyl inositol 4,5 biphosphate to the second messenger 
inositol 1,4,5-triphosphate (IP3), which determines the release of Ca2+ from 
the endoplasmic reticulum via the inositol 1,4,5-trisphosphate receptor (IP3R) 
channel and consequently allows cell depolarisation and message delivery.  
By inhibiting PDE-4, apremilast (in red) increases intracellular cAMP levels 
and activates PKA which, by phosphorylating IP3R, prevents the release of 
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Ca2+, gustatory cell depolarisation, and the delivery of the sweet taste 
message. 
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